Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Florida Cancer Specialists Physician Studies Featured at American Society of Clinical Oncology 2022 Gastrointestinal Cancers Symposium

February 2, 2022
Article

In Partnership With

Florida Cancer Specialist & Research Institute is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state.

Fort Myers, Fla., Jan. 24, 2022 – Studies conducted by physicians at Florida Cancer Specialists & Research Institute, LLC (FCS) were featured in poster presentations at American Society of Clinical Oncology (ASCO) 2022 Gastrointestinal Cancers Symposium held in San Francisco, California January 20 – 22, 2022. FCS is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state. Over the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with FCS participation, prior to approval.

The ASCO GI 2022 Symposium provides a global multidisciplinary forum for new, innovative research related to GI cancer care, highlighting experts who are converting science into optimal patient care. The abstract “Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC),” includes observations from FCS physicians, Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, who were co-authors. This Phase II study, evaluating the effectiveness of an anti-PD-1 antibody, combined with other agents, found antitumor activity comparable to third-line therapy for this patient population.

“The ability to be involved in cutting edge treatments in my private practice that are saving lives is an innovative approach that has touched so many, saved and changed lives, and moved medicine forward,” said FCS Hematologist and Medical Oncologist Dr. Ivor Percent. “It has allowed the doctors on the front lines to do what we signed up for – to give the newest and greatest treatments, prolong quality of life, and save lives, if not now, in 5 years.”

“A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors,” another presentation at ASCO GI 2022, includes observations from FCS physician, Manish R. Patel, MD. This study evaluates the safety, maximum tolerated dose (MTD), pharmacokinetics (PK) profile and preliminary anti-cancer effect of TST001 in patients with locally advanced or metastatic solid gastric tumors.

To view an online version of the abstracts, visit: abstracts.asco.org

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

Jordyn Sava
July 1st 2025
Article

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.

Read More


Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen


First Patient Imaged in Phase 3 AMPLIFY Trial for BCR of Prostate Cancer

First Patient Imaged in Phase 3 AMPLIFY Trial for BCR of Prostate Cancer

Jordyn Sava
May 29th 2025
Article

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.

Read More


Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies

Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies

Jordyn Sava
May 22nd 2025
Article

Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.

Read More


Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors

Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors

Jordyn Sava
May 19th 2025
Article

A phase 1 trial of mRNA-4106 has dosed its first patient with an advanced or metastatic solid tumor.

Read More


IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

Jordyn Sava
May 7th 2025
Article

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Read More

Related Content

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

Jordyn Sava
July 1st 2025
Article

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.

Read More


Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen


First Patient Imaged in Phase 3 AMPLIFY Trial for BCR of Prostate Cancer

First Patient Imaged in Phase 3 AMPLIFY Trial for BCR of Prostate Cancer

Jordyn Sava
May 29th 2025
Article

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.

Read More


Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies

Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies

Jordyn Sava
May 22nd 2025
Article

Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.

Read More


Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors

Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors

Jordyn Sava
May 19th 2025
Article

A phase 1 trial of mRNA-4106 has dosed its first patient with an advanced or metastatic solid tumor.

Read More


IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma

Jordyn Sava
May 7th 2025
Article

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.